a subsidiary of IPSEN
  • Tercica, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of short stature and other endocrine disorders.

    June 4th, 2008, Tercica, announced that Tercica and Ipsen, S.A. entered into a definitive merger agreement by which an affiliate of Ipsen would acquire all of the shares of Tercica common stock that Ipsen does not currently own at a price of $9.00 per share in cash, which values Tercica at approximately $663 million.
  • Snapshot

    Business TypeSectorSubsectorFounded
    Start-up / RnDDrug DevelopmentOncology
  • Key People

    CEODr John Scarlett
    CFOAjay Bansa
    CSODr George Bright
Registered Office651 Gateway Boulevard Suite 950
San Francisco, CA 94080-7111
Tel. +1 650 624 4900
Web Sitehttp://www.tercica.com